scholarly journals Extranodal non-Hodgkin’s lymphoma: A case series at a tertiary care hospital

2020 ◽  
Vol 5 (4) ◽  
pp. 302-305
Author(s):  
Pomilla Singh ◽  
◽  
Ravi Swami ◽  
Shashank Singh ◽  
N S Mani ◽  
...  
Keyword(s):  
Hodgkin’S Lymphoma ◽  
Tertiary Care Hospital ◽  
Tertiary Care ◽  
Case Series ◽  
Hodgkin's Lymphoma ◽  
Care Hospital ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma

scholarly journals Non-Hodgkin’s lymphoma and spinal cord compression: a diagnostic challenge

2015 ◽  
Vol 9 (4) ◽  
pp. 380
Author(s):  
Bilal Bin Abdullah ◽  
Nida Nausheen ◽  
Nagur Khuda Baksh ◽  
Naga Dharma Teja Keerthi
Keyword(s):  
Spinal Cord ◽  
Spinal Cord Compression ◽  
Hodgkin’S Lymphoma ◽  
Tertiary Care ◽  
Cord Compression ◽  
Hodgkin's Lymphoma ◽  
Care Hospital ◽  
Diagnostic Challenge ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma

We report a 25-year-old lady presenting to the outpatient department of a tertiary care hospital with spinal cord compression. Initially we had a diagnostic difficulty, as its presentation was perplexing. Finally we pointed towards the diagnosis of non- Hodgkin’s lymphoma and proved it. This article carries a message for the clinicians as clinical fallacies were noticed towards pointing this diagnosis. We have clearly explained the shortcomings in evaluating a case making a diagnosis towards non- Hodgkin’s lymphoma and spinal cord compression, as many situations in the setting were simulating and overlapping.

Delays in the Cancer Pathway from Symptom Onset to Initiation of Treatment – A Retrospective Study in Patients with Non-Hodgkin’s Lymphoma.

Blood ◽  
2006 ◽  
Vol 108 (11) ◽  
pp. 347-347 ◽  
Author(s):  
Reem Nassur ◽  
Joy Mangel ◽  
Ian Chin-Yee
Keyword(s):  
Waiting Time ◽  
Symptom Onset ◽  
Hodgkin’S Lymphoma ◽  
Tertiary Care ◽  
Significant Proportion ◽  
Pathological Diagnosis ◽  
Hodgkin's Lymphoma ◽  
Patient Anxiety ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma

Abstract Background: Cancer patients may experience significant delays along the clinical pathway from the onset of symptoms to initiation of treatment. Few studies have examined the nature or the extent of these delays in patients with non-Hodgkin’s lymphoma (NHL). Method: London Regional Cancer Program (LRCP) is a tertiary care centre with a referral base of 1.5 million people in Southwestern Ontario. In this study, the charts of all patients with newly diagnosed NHL that were seen at the LRCP between Jan 1 – Dec 31, 2004 were reviewed retrospectively in order to measure and document the amount of time spent at each stage of the cancer pathway. Key time intervals from symptom onset to initiation of treatment were recorded. Associations between the waiting times and clinical/sociodemographic factors were also explored. Results: The charts of 116 patients were reviewed. The median overall waiting time from symptom onset to the initiation of treatment was 137 days. Median waiting time for each interval in the pathway were as follows: from symptom onset to first visit with primary care physician: 17 days; from first visit with physician to surgical consultation: 28 days; from surgical consult to the definitive biopsy: 13 days; from definitive biopsy to pathological diagnosis: 10 days; from pathological diagnosis to hematology referral: −5 days; from hematology referral to hematology consultation: 8 days; from hematology consult to completion of staging: 8 days; and from final staging to initiation of treatment: 5 days. The time from symptom onset to treatment initiation varied somewhat by clinical factors such as gender, age, and presence of B-symptoms. Patients with B-symptoms experienced shorter delays (119 d) than patients without B-symptoms (154 d). Male patients had shorter pathway times (113 d) compared to female patients (138 d). Patients at the extremes of age (age 20–29 & age >80) tended to have shorter delays than patients between the ages of 30–79 (ages 20–29: 60d, age >80: 85d, ages 30–79:137 d). Whether patients were referred from London vs. from another municipality did not appear to influence delays (137 d). Conclusions: NHL patients are experiencing significant delays in the assessment and treatment of their cancer. Most prior studies have focused primarily on delays from the point of referral to a cancer specialist to initiation of treatment. The results from our study suggest that a significant proportion of the patient’s clinical path is being spent at the prediagnosis phase (from the time of first physician visit until pathological diagnosis, 57 days) as opposed to from the time of diagnosis until the initiation of treatment (18 days). Efforts to reduce delays at both the pre- and post-diagnosis phases of the patient path may reduce patient anxiety with subsequent improvements in quality of life. The clinical impact of these delays on patient outcome is uncertain and requires further study.

scholarly journals Adult Non Hodgkin's Lymphoma Patients: Experience from a Tertiary Care Cancer Centre in North East India

2015 ◽  
Vol 16 (7) ◽  
pp. 2879-2881 ◽  
Author(s):  
Munlima Hazarika ◽  
Asif Iqbal ◽  
Manigreeva Krishnatreya ◽  
Jagannath Dev Sharma ◽  
Chidananda Bhuyan ◽  
...  
Keyword(s):  
Hodgkin’S Lymphoma ◽  
Tertiary Care ◽  
Hodgkin's Lymphoma ◽  
Cancer Centre ◽  
North East India ◽  
North East ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma ◽  
Patients Experience

scholarly journals SLE and Non-Hodgkin’s Lymphoma: A Case Series and Review of the Literature

2017 ◽  
Vol 2017 ◽  
pp. 1-7 ◽  
Author(s):  
Prajwal Boddu ◽  
Abdul S. Mohammed ◽  
Chandrahasa Annem ◽  
Winston Sequeira
Keyword(s):  
Risk Factors ◽  
Lupus Erythematosus ◽  
Hodgkin’S Lymphoma ◽  
Primary Cns Lymphoma ◽  
Case Series ◽  
Hodgkin's Lymphoma ◽  
Cns Lymphoma ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma

Systemic lupus erythematosus (SLE) is a multisystem autoimmune disorder punctuated by varied multiorgan complications all along the course of its natural history. Lymphoma represents a relatively well-recognized malignant phenomenon associated with lupus. The cause and effect relationships of lymphoma in SLE have been subject to extensive scrutiny with several studies reporting on clinic-pathologic characteristics and risk factors predicting lymphoma development in SLE. However, the pathogenic role of immunosuppressives in SLE-related lymphoma still remains unclear, and indices to help guide diagnosis, prognostication, therapy, and posttreatment monitoring are yet to be established. In this review, we describe 3 SLE patients who developed non-Hodgkin’s lymphoma at different time points of their disease. Through a careful dissection of the aforementioned cases, we intend to apprise readers of the currently available literature surrounding risk factors, management, and prognosis in SLE-related lymphoma. We will also review and discuss the implications of immunosuppressives in SLE-related lymphoma and the role of mycophenolate mofetil in SLE-related primary CNS lymphoma development.

scholarly journals Paraneoplastic diseases associated with non-Hodgkin’s lymphoma – Case series

2020 ◽  
Vol 5 (3) ◽  
pp. 66-69
Author(s):  
Abhraneel Guha ◽  
Kundan Chaurasia ◽  
Bhaswati Dasgupta Nath ◽  
Raja Basu ◽  
Avijit Das ◽  
...  
Keyword(s):  
Hodgkin’S Lymphoma ◽  
Case Series ◽  
Hodgkin's Lymphoma ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma ◽  
Paraneoplastic Diseases
Sign in / Sign up

Export Citation Format

Share Document